Search
fostemsavir (Rukobia)
Indications:
- treatment-resistant HIV1 infection
Dosage:
- 600 mg q12 hours
Adverse effects:
- nausea (most common)
- elevations in serum transaminases among patients with hepatitis B or hepatitis C
- immune reconstitution syndrome
Mechanism of action:
- prodrug of temsavir
- HIV1 glycoprotein 120 (gp120) attachment inhibitor
- binds directly to the gp120 subunit on the surface of HIV1
Interactions
drug adverse effects of antiretroviral agents
General
antiretroviral agent
Database Correlations
PUBCHEM correlations
References
- FDA NEWS RELEASE. July 02, 2020
FDA Approves New HIV Treatment for Patients With Limited Treatment Options.
https://www.fda.gov/news-events/press-announcements/fda-approves-new-hiv-treatment-patients-limited-treatment-options
- Kozal M, Aberg J, Pialoux G et al
Fostemsavir in Adults with Multidrug-Resistant HIV-1 Infection.
N Engl J Med. 2020 Mar 26;382(13):1232-1243.
PMID: 32212519 Clinical Trial.